Skip to Main Content

Paper Details

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Clin Cancer Res
17
2022
Author NameAffiliation
Jonathan W GoldmanDavid Geffen School of Medicine, university of california los angeles
Jonathan W GoldmanDavid Geffen School of Medicine, university of california los angeles
  • 1 - 2

Datasets

Release 1.2